Literature DB >> 158324

NIH conference. Systemic lupus erythematosus: evolving concepts.

J L Decker, A D Steinberg, J L Reinertsen, P H Plotz, J E Balow, J H Klippel.   

Abstract

Systemic lupus erythematosus, a disease of unknown cause and protean manifestations, continues to excite substantial investigational interest. These papers bring together recent advances in concepts of its immunopathogenesis, evidence for a major genetic role in the causation of the process, developing systems for the morphologic assessment of its often fatal nephritis, and data from ongoing trials of cytotoxic drugs in its management.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 158324     DOI： 10.7326/0003-4819-91-4-587

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


  33 in total

1.  Relation between serological data at the time of biopsy and renal histology in lupus nephritis.

Authors:  J C Nossent; S C Henzen-Logmans; T M Vroom; V Huysen; J H Berden; A J Swaak
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

2.  Vasculitides throughout history and their clinical treatment today.

Authors:  Antonio Iglesias-Gamarra; Edgar Penaranda; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2011-12       Impact factor: 4.592

3.  Long-term outcome of patients with lupus nephritis: a single center experience.

Authors:  Senija Rasić; Amira Srna; Snezana Uncanin; Jasminka Dzemidzić; Damir Rebić; Alma Muslimović; Maida Rakanović-Todić; Aida Hamzić-Mehmedbasić
Journal:  Bosn J Basic Med Sci       Date:  2010-04       Impact factor: 3.363

4.  The effect of the immunomodulator agent AS101 on interleukin-2 production in systemic lupus erythematosus (SLE) induced in mice by a pathogenic anti-DNA antibody.

Authors:  M Blank; B Sredni; M Albeck; E Mozes; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

5.  The B-cell activation pathway in human systemic lupus erythematosus: imbalanced in vitro production of lymphokines and association with serum analytical findings.

Authors:  M L Gaspar; M Alvarez-Mon; C Gutierrez
Journal:  J Clin Immunol       Date:  1988-07       Impact factor: 8.317

6.  Production of a suppressor factor by human adherent cells treated with Mycobacterium tuberculosis: absence in systemic lupus erythematosus.

Authors:  A A Wadee; A J Gear; A R Rabson
Journal:  Clin Exp Immunol       Date:  1981-10       Impact factor: 4.330

7.  Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE).

Authors:  H Groen; M Aslander; H Bootsma; T W van der Mark; C G Kallenberg; D S Postma
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

8.  Enhanced membrane binding of autoantibodies to cultured keratinocytes of systemic lupus erythematosus patients after ultraviolet B/ultraviolet A irradiation.

Authors:  T D Golan; K B Elkon; A E Gharavi; J G Krueger
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

9.  Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids.

Authors:  E M Lafer; J Rauch; C Andrzejewski; D Mudd; B Furie; B Furie; R S Schwartz; B D Stollar
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

10.  Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers.

Authors:  W L Sibbitt; P M Mathews; A D Bankhurst
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.